DOPAMINE-D1 RECEPTOR ANTAGONISM IN SCHIZOPHRENIA - IS THERE REDUCED RISK OF EXTRAPYRAMIDAL SIDE-EFFECTS

被引：25

作者：

HIETALA, J ^{[1
]}

LAPPALAINEN, J ^{[1
]}

KOULU, M ^{[1
]}

SYVALAHTI, E ^{[1
]}

机构：

[1] ACAD FINLAND, MRC, SF-20520 TURKU 52, FINLAND

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 1990年 / 11卷 / 10期

关键词：

(-)-trans-6; 1-b)azepine; 13()-hexahydro-3-chloro-2-hydroxy-N-methyl-5H-benzo(d)naphtho-(2; 3; 4; 5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol SCH39166; 7; 8; 9; n; R-(+)-8-chloro-2;

D O I：

10.1016/0165-6147(90)90147-Z

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The first selective D1 dopamine receptor antagonist, SCH23390, has been reported to be active in preclinical tests that predict antipsychotic activity in schizophrenic patients. This is particularly exciting because it has been claimed that this compound is 'atypical', in that it has a reduced propensity to induce extrapyramidal side-effects. However, in considering the evidence from preclinical screening tests for antipsychotic activity and extrapyramidal sideeffects of potential neuroleptic drugs, Jarmo Hietala and colleagues conclude that the majority of available data is not compatible with the postulated atypical profile of SCH23390. © 1990.

引用

页码：406 / 410

页数：5

共 40 条

[1] SOME ATYPICAL NEUROLEPTICS INHIBIT [H-3] SCH 23390 BINDING INVIVO [J].